Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension

Anna Galanopoulos1, Ivan Goldberg21Senior Visiting Ophthalmologist, South Australian Institute of Ophthalmology and Dept of Ophthalmology and Visual Sciences, University of Adelaide, South Australia; 2Clinical Associate Professor, University of Sydney, Australia; Head, Glaucoma Unit, Sydney Eye Hosp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Galanopoulos, Ivan Goldberg
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/eb440bd0135d4fe88ba06a90c277e32b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb440bd0135d4fe88ba06a90c277e32b
record_format	dspace
spelling	oai:doaj.org-article:eb440bd0135d4fe88ba06a90c277e32b2021-12-02T04:29:05ZClinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension1177-54671177-5483https://doaj.org/article/eb440bd0135d4fe88ba06a90c277e32b2008-12-01T00:00:00Zhttp://www.dovepress.com/clinical-efficacy-and-neuroprotective-effects-of-brimonidine-in-the-ma-a2707https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Anna Galanopoulos1, Ivan Goldberg21Senior Visiting Ophthalmologist, South Australian Institute of Ophthalmology and Dept of Ophthalmology and Visual Sciences, University of Adelaide, South Australia; 2Clinical Associate Professor, University of Sydney, Australia; Head, Glaucoma Unit, Sydney Eye Hospital, Sydney, Australia, Director, Eye Associates, Sydney, AustraliaAbstract: Elevated intraocular pressure (IOP) is a significant risk factor for the development and progression of glaucomatous optic neuropathy, but increasingly we appreciate that non-pressure dependent factors, are key to our understanding of the pathophysiology of these neurodegenerative diseases, that target the retinal ganglion cell. As we try to expand therapy beyond IOP control, medications are being assessed for their neuroprotective abilities. Brimonidine is an effective ocular hypotensive treatment both as a first and second line agent, in the management of glaucoma and ocular hypertension. Brimonidine tartrate 0.2% is generally safe and well tolerated, with its safety profile further enhanced in the altered formulation brimonidine-Purite&trade; 0.1%. Beyond brimonidine&rsquo;s pressure lowering capacity, laboratory and early clinical evidence supports its neuroprotective potential. We await validation of this in human clinical trials.Keywords: brimonidine, neuroprotection, clinical effectiveness, tolerability Anna GalanopoulosIvan GoldbergDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 117-122 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Anna Galanopoulos Ivan Goldberg Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
description	Anna Galanopoulos1, Ivan Goldberg21Senior Visiting Ophthalmologist, South Australian Institute of Ophthalmology and Dept of Ophthalmology and Visual Sciences, University of Adelaide, South Australia; 2Clinical Associate Professor, University of Sydney, Australia; Head, Glaucoma Unit, Sydney Eye Hospital, Sydney, Australia, Director, Eye Associates, Sydney, AustraliaAbstract: Elevated intraocular pressure (IOP) is a significant risk factor for the development and progression of glaucomatous optic neuropathy, but increasingly we appreciate that non-pressure dependent factors, are key to our understanding of the pathophysiology of these neurodegenerative diseases, that target the retinal ganglion cell. As we try to expand therapy beyond IOP control, medications are being assessed for their neuroprotective abilities. Brimonidine is an effective ocular hypotensive treatment both as a first and second line agent, in the management of glaucoma and ocular hypertension. Brimonidine tartrate 0.2% is generally safe and well tolerated, with its safety profile further enhanced in the altered formulation brimonidine-Purite&trade; 0.1%. Beyond brimonidine&rsquo;s pressure lowering capacity, laboratory and early clinical evidence supports its neuroprotective potential. We await validation of this in human clinical trials.Keywords: brimonidine, neuroprotection, clinical effectiveness, tolerability
format	article
author	Anna Galanopoulos Ivan Goldberg
author_facet	Anna Galanopoulos Ivan Goldberg
author_sort	Anna Galanopoulos
title	Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
title_short	Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
title_full	Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
title_fullStr	Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
title_full_unstemmed	Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
title_sort	clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/eb440bd0135d4fe88ba06a90c277e32b
work_keys_str_mv	AT annagalanopoulos clinicalefficacyandneuroprotectiveeffectsofbrimonidineinthemanagementofglaucomaandocularhypertension AT ivangoldberg clinicalefficacyandneuroprotectiveeffectsofbrimonidineinthemanagementofglaucomaandocularhypertension
_version_	1718401222474465280

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension

Ejemplares similares